Penumbra
About: Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
Employees: 4,200
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]
17% more call options, than puts
Call options by funds: $68.5M | Put options by funds: $58.6M
5% more capital invested
Capital invested by funds: $6.52B [Q2] → $6.87B (+$353M) [Q3]
9% less first-time investments, than exits
New positions opened: 51 | Existing positions closed: 56
2.47% less ownership
Funds ownership: 93.48% [Q2] → 91.0% (-2.47%) [Q3]
3% less funds holding
Funds holding: 339 [Q2] → 328 (-11) [Q3]
29% less repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 139
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
10 analyst ratings
Baird David Rescott 81% 1-year accuracy 13 / 16 met price target | 14%upside $305 | Outperform Maintained | 23 Jan 2025 |
UBS Priya Sachdeva 0% 1-year accuracy 0 / 2 met price target | 14%upside $305 | Buy Initiated | 21 Jan 2025 |
Truist Securities Richard Newitter 74% 1-year accuracy 31 / 42 met price target | 6%upside $285 | Buy Maintained | 18 Dec 2024 |
Oppenheimer Steve Lichtman 100% 1-year accuracy 2 / 2 met price target | 2%upside $275 | Outperform Initiated | 17 Dec 2024 |
Citigroup Joanne Wuensch 66% 1-year accuracy 31 / 47 met price target | 9%downside $245 | Neutral Maintained | 11 Dec 2024 |
Financial journalist opinion









